Conference Roundup
Thyroid Eye Disease

Teprotumumab treatment effect may be due to IGF-1 signaling disruption

Posted on

New study data presented at AAO 2022 reveals a specific molecular signature for acute and chronic thyroid eye disease.

During a presentation, Shoaib Ugradar, MD shared the results of entire genome RNA sequencing and pathway analysis in orbital tissue from patients with acute (n = 8) and chronic (n = 8) TED, as well as 5 controls.

Acute disease was found to have activation of immune system pathways; these pathways appear to be relatively unaffected in chronic disease. In acute and chronic patients,  upregulation of IGF-1, its related pathways and extracellular matrix organization, was found to be extensive.

“These observations suggest chronic disease is not inactive. Further, treatment effects of teprotumumab in both chronic and acute disease may be due to the disruption of IGF-1 signaling,” Dr Ugradar concluded.

Ugradar S, et al. Whole Genome Transcriptome Comparison of Acute and Chronic Thyroid Eye Disease: Emergence of a Molecular Signature. Presented at: AAO 2022.